VISTA PHARMACEUTICALS LTD. (VISTAPH) Fair Value & Analysis
Healthcare · IN · Market cap ₹451M
Risks
Fair value as of: Aug 17, 2026
From 1 valuation models · updated 4 days ago
Share price −11.4% over the past month.
Below-average quality, and screening another 52% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹4.50). The favourable scenario is already priced in.
- Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (₹2.25 to ₹4.50) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
60‑month range ₹5.80 – ₹19.32 · fair‑value band ₹2.25 – ₹4.50 · the ₹6.30 price screens above the ₹3.02 fair value. Dashed = 300-day average. As of Aug 17, 2026.
Analysis
VISTA PHARMACEUTICALS LTD. (VISTAPH) currently trades at ₹6.30, while our model-based Fair Value estimate is ₹3.02, implying the stock looks roughly 52.1% overvalued today. The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, VISTA PHARMACEUTICALS LTD. generated revenue of ₹86.3M at a net margin of -89.2%. Revenue declined 5.4% year over year. It earns a return on equity of -14.4%. Net debt stands at ₹98.8M. Fundamentals as of Aug 17, 2026
Our scenario range runs from ₹2.25 (bear case) to ₹4.50 (bull case); at ₹6.30, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at -52%, VISTAPH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when VISTAPH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 24 · Market factors (momentum, volatility) 23
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India, the United States, and internationally. It offers over the counter and prescription generic drugs consisting of tablets, capsules, and liquids covering various therapeutic categories.
Full company description
Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India, the United States, and internationally. It offers over the counter and prescription generic drugs consisting of tablets, capsules, and liquids covering various therapeutic categories. Vista Pharmaceuticals Limited was incorporated in 1991 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
VISTA PHARMACEUTICALS LTD. reported revenue of ₹54.0M in FY2026 versus ₹3.9M in FY2022, a compound +92.3%/yr. Reported net income was −₹121M in FY2026.
VISTAPH screens 52% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 638 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$56.05 | HK$33.59 | -40% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare VISTA PHARMACEUTICALS LTD. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is VISTA PHARMACEUTICALS LTD. (VISTAPH) overvalued or undervalued?
What is the fair value of VISTAPH?
What is the quality score of VISTAPH?
What is the revenue of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the net profit margin of VISTAPH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track VISTA PHARMACEUTICALS LTD. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.